MOMA Therapeutics is a private company. Its most recent disclosed valuation is $350M. Its shares do not trade on a public exchange.
One company valuation: $350M, dated Apr 2023.
MOMA Therapeutics is a precision-medicine biotech company that discovers drugs by targeting molecular machines, the highly dynamic proteins that underlie human disease. The company is based in the United States and describes itself as a clinical-stage company applying this approach to cancer and other conditions.
In 2022 MOMA raised $150 million in a Series B financing round to advance its precision oncology programs, and in 2024 it entered a five-year discovery collaboration with Roche focused on critical cancer dependencies.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds MOMA Therapeutics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. MOMA Therapeutics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — MOMA Therapeutics included.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. MOMA Therapeutics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
